EQL Pharma out-license Mellozzan to a leading European pharmaceutical Company for two major Southern European geographies
EQL Pharma has today entered into an exclusive out-licensing agreement with a leading European pharmaceutical company for EQL's proprietary product Mellozzan (melatonin) for two major geographies in Southern Europe. The agreement is in practice without a set time limit and applies to tablets in six different strengths as well as an oral solution. Both formulations are ready to send in for registration in the two countries.
Mellozzan is a medicine given to children with sleep disorders who have ADHD and where sleep hygiene measures are not enough. In the ADHD patient group insomnia is very common, often exacerbated by treatment with central stimulants such as methylphenidate or dexamphetamine. It can also be given as a short-term treatment to adults with sleep disorders caused by jet lag. Mellozzan was launched by EQL in Sweden in 2021, and EQL's ambition is to offer the product in all interesting markets in Europe and elsewhere via out-licensing.
The strategic partner is one of the most successful pharmaceutical holdings in Europe, with extensive resources in sales and marketing across a number of countries.
“We are extremely happy and proud that we will now be able to offer Mellozzan in Southern Europe where there is currently no corresponding product for treating sleep disorders in children with ADHD. In Sweden, melatonin treatment for children with ADHD and sleep disorders has reached a total treatment volume of well over 60 million tablets per year, distributed among some original players, including Mellozzan. We see our new partner as the perfect one who has the know-how, the network of specialists and with the interface to authorities, that is necessary to reach this large group of patients in a fast and safe way in these important markets." says Axel Schörling, CEO of EQL.
The agreement includes a consideration of few hundred thousand EUR in down payment and regulatory milestones subject to fulfilment of certain regulatory and commercial conditions, and a supply price with a double-digit percentage over the net selling price. The launch of Mellozzan in Southern Europe will take place as soon as possible, mainly governed by processing times at authorities for registration and reimbursement.
EQL Pharma has advanced negotiations regarding Mellozzan with several other companies for additional countries in and outside of Europe.
För ytterligare information, vänligen kontakta:
Axel Schörling
VD & Koncernchef EQL Pharma AB (publ)
Telefon: +46 (0) 763 – 17 90 60
E-post: axel.schorling@eqlpharma.com
Hemsida: www.eqlpharma.com
EQL Pharma AB (publ) in short
EQL Pharma AB specializes in developing and selling niche pharmaceuticals. The company currently has more than 20 niche generics (ie generics with limited competition apart from the reference pharmaceutical) approved in the Nordic markets and a couple of originals. In addition to these, there is a significant pipeline of mainly niche generics for launch in 2022 and beyond. The business is currently entirely focused on prescription pharmaceuticals, including hospital products, in the Nordic region and in selected European markets. EQL Pharma AB conducts its operations in Lund and is listed on the Spotlight Stock Market. EQL Pharma AB conducts extensive development work in collaboration with leading contract manufacturers and pharmaceutical companies in the EU and Asia, among others.